Evidence map›Paper›PMID 32132681›Full record

ReviewNature reviews. Immunology2020

Defining trained immunity and its role in health and disease.

Mihai G Netea, Jorge Domínguez-Andrés, Luis B Barreiro, Triantafyllos Chavakis, Maziar Divangahi, Elaine Fuchs, Leo A B Joosten, Jos W M van der Meer, Musa M Mhlanga, Willem J M Mulder and 7 more

7 registry-linked trialsAbstract readReview
In one paragraph

Review in Nature reviews. Immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 1,575 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,575citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03305341 early_phase1active not recruitingnot on this mapstarted 2025, after this paper: background citation

Conducting an Initial Small, Controlled Clinical Pharmacology Trial to Assess for Therapeutic Biologics Activity (Proof-of-Concept) That Suggests the Potential for Clinical Benefits of COVID-19 Patients With Controlled Cancers.

TypeinterventionalSponsorHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairRan2025 to 2026Enrolled20ConditionsCovid19ArmsCOVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use
NCT04375176 unknown statusnot on this map

Study of Immune-mediated Mechanisms in Patients Tested Positive for SARS-CoV-2: Phenotypic and Functional Analysis of Monocytes and NK Cells in the Blood of Subjects Affected by Covid 19

TypeobservationalSponsorUniversità degli Studi dell'InsubriaRan2020 to 2020Enrolled150ConditionsCOVID-19, Severe Acute Respiratory Syndrome Coronavirus 2, ImmunomodulationArmsStudy of immune-mediated mechanisms in patients tested positive for SARS-CoV-2
NCT04384549 phase3unknown statusnot on this map

Randomized Controlled Trial Evaluating the Efficacy of Vaccination With Bacillus Calmette and Guérin (BCG) in the Prevention of COVID-19 Via the Strengthening of Innate Immunity in Health Care Workers

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2020 to 2021Enrolled1,120ConditionsInfection, Viral, Agent as Cause of Disease Classified ElsewhereArmsBCG GROUP, PLACEBO GROUP
NCT04534803 phase3withdrawnnot on this mapstarted 2021, after this paper: background citation

Bacillus Calmette-Guerin Against Covid-19 for Prevention and Amelioration of Severity Trial

TypeinterventionalSponsorHarvard Medical School (HMS and HSDM)Ran2021 to 2022Enrolled0ConditionsCovid19ArmsBCG Vaccine, Placebo
NCT05208060 phase1 / phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

A Phase I/II Randomized, Prospective, Double-blind, Placebo-controlled, Single-center Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells

TypeinterventionalSponsorInmunotek S.L.Ran2023 to 2025Enrolled48ConditionsImmune ResponseArmsMV130, Placebo
NCT07182838 early_phase1active not recruitingnot on this mapstarted 2025, after this paper: background citation

Conducting an Initial Small, Controlled Clinical Pharmacology Trial to Assess for Therapeutic Biologics Activity (Proof-of-Concept) That Suggests the Potential for Clinical Benefits of HIV (+) Patients

TypeinterventionalSponsorHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairRan2025 to 2026Enrolled20ConditionsHIV InfectionsArmsHIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous use
NCT07527247 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Using AS01 Adjuvant to Improve Immune Response in Older Adults Through Trained Immunity

TypeinterventionalSponsorSingapore General HospitalRan2025 to 2029Enrolled40ConditionsImmune System Responses and Trained Immunity After AS01 Administration, Healthy AdultArmsAS01 adjuvant (0.5 mL intramuscular), YF17D (Stamaril, Sanofi-Pasteur), Placebo (NaCl 09%, 0.5mL)
3 · Its place in the literature

Who cites it

1,575 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Mucosal immunity and vaccine development.Signal transduction and targeted therapy · 2026
    Pooled it
  2. Trial
  3. Review
  4. Resetting immunometabolic set points in autoimmune disease.Journal of translational autoimmunity · 2026
    Review
  5. Review
  6. Article
  7. Monocytes in pneumonia: Functional plasticity and innate memory (Review).International journal of molecular medicine · 2026
    Review
  8. Review
  9. Article
  10. Article
  11. Good neighbors make lasting memory.Nature immunology · 2026
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Peripheral immune-cell bioenergetics in acute and stable schizophrenia.European archives of psychiatry and clinical neuroscience · 2026
    Article
  19. Article
  20. Review

1,515 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mihai G NeteaDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands. Mihai.Netea@radboudumc.nl.ORCID http://orcid.org/0000-0003-2421-6052
Jorge Domínguez-AndrésDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
Luis B BarreiroDepartment of Genetics, CHU Sainte-Justine Research Centre, Montreal, QC, Canada.
Triantafyllos ChavakisInstitute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden, Dresden, Germany.
Maziar DivangahiMeakins-Christie Laboratories, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.
Elaine FuchsHoward Hughes Medical Institute, Robin Chemers Laboratory of Mammalian Cell Biology and Development, The Rockefeller University, New York, NY, USA.
Leo A B JoostenDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
Jos W M van der MeerDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
Musa M MhlangaDivision of Chemical and Systems Biology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Willem J M MulderTranslational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Niels P RiksenDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
Andreas SchlitzerMyeloid Cell Biology, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany.
Joachim L SchultzeDepartment of Genomics and Immunoregulation, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany.
Christine Stabell BennBandim Health Project, OPEN, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Joseph C SunImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ramnik J XavierBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Eicke LatzInstitute of Innate Immunity, University Hospital, University of Bonn, Bonn, Germany. eicke.latz@uni-bonn.de.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
VITAMIN A AND KERATINIZATION IN HUMAN EPITHELIAL CELLSR01AR031737 · NIAMS · UNIVERSITY OF CHICAGO · PI ELAINE FUCHS · 1986 to 2026
$16.6M
Skin Stem Cells: Purification and CharacterizationR01AR050452 · NIAMS · ROCKEFELLER UNIVERSITY · PI ELAINE FUCHS · 2004 to 2026
$8.6M
The natural killer cell response against mouse cytomegalovirus infectionR01AI100874 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI Joseph Chai-Yuen Sun · 2012 to 2026
$7.4M
HDL prevention of cholesterol crystal inflammation in HIV diseaseR01HL112661 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI FITZGERALD, MICHAEL LEO, LATZ, EICKE · 2012 to 2016
$3.1M
Regulation of Nfil3 in innate lymphocyte-mediated host immunityR01AI130043 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI SUN, JOSEPH CHAI-YUEN · 2017 to 2021
$2.8M
European Research Council 683145Howard Hughes Medical InstituteNCI NIH HHS P30 CA008748NHLBI NIH HHS R01 HL112661NIAID NIH HHS R01 AI100874NIAID NIH HHS R01 AI130043NIAMS NIH HHS R01 AR031737NIAMS NIH HHS R01 AR050452
6 · The paper itself

Abstract

Immune memory is a defining feature of the acquired immune system, but activation of the innate immune system can also result in enhanced responsiveness to subsequent triggers. This process has been termed 'trained immunity', a de facto innate immune memory. Research in the past decade has pointed to the broad benefits of trained immunity for host defence but has also suggested potentially detrimental outcomes in immune-mediated and chronic inflammatory diseases. Here we define 'trained immunity' as a biological process and discuss the innate stimuli and the epigenetic and metabolic reprogramming events that shape the induction of trained immunity.

Indexed as

Adaptive ImmunityAnimalsEpigenesis, GeneticHumansImmune SystemImmune System DiseasesImmune ToleranceImmunity, InnateImmunologic MemoryInflammation

Identifiers

PMID32132681
PMCPMC7186935

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.